A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

Patients must have:

• Met the CDC criteria for the diagnosis of AIDS.
• Total peripheral blood leukocyte count = or \< 3000 cells/mm3 measured on at least two occasions separated by a minimum of one week.
• Must have or have recovered from one or more opportunistic infection.
• Serum antibody to HTLV-III/LAV with or without viremia.
• Anticipated survival of at least 6 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• AIDS related complex (ARC).
• History of malignancy other than Kaposi's sarcoma (KS).
• Excessive diarrhea (more than 5 liquid or non-liquid stools per day).
• Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infections.
• Presence of renal dysfunction.
• Other evidence of primary hematologic or infectious disorders unrelated to AIDS virus infection.

Patients with the following are excluded:

• AIDS related complex (ARC).
• History of malignancy other than Kaposi's sarcoma (KS).
• Excessive diarrhea (more than 5 liquid or non-liquid stools per day).
• Currently hospitalized or hospitalized within the last 4 weeks for the treatment of an opportunistic infection.
• Dementia or altered mental status that would prohibit the giving and understanding of informed consent.

Prior Medication:

Excluded:

• Any marrow suppressive medications such as trimethoprim-sulfamethoxazole combination (TMP-PurposeX) or Fansidar.
• Excluded within 6 weeks of study entry:
• Any investigational drug.

Prior Treatment:

Excluded within 6 weeks of study entry:

• Systemic cytotoxic chemotherapy or irradiation.

Risk Behavior:

Excluded within 3 months of study entry:

• Regular, excessive use of alcohol, hallucinogens or agents which are addicting.